Pharma companies (except Pfizer and NovoNordisk) slip in investor rankings
This article was originally published in Scrip
Executive Summary
Pharmaceutical and biotech companies have lost ground in the 15th FT Global 500, which provides an annual snapshot of the world's largest companies ranked by market capitalisation. The relative performance of pharma and biotech companies underpins the challenge they face when attempting to attract the attention of fund managers (scripintelligence.com, 13 June, 2011).